-
Express In view of the common genetic risk of Parkinson's disease, Xinrui has reached a gene therapy cooperation
Time of Update: 2023-02-01
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec content team editorNeurocrine Biosciences and Voyager Therapeutics today announced a new strategic collaboration to advance multiple gene therapies for the treatment of neurological disorders.
-
Express is expected to come out early next year, and myasthenia gravis therapy has been prioritized by the FDA
Time of Update: 2023-01-05
S. Food and Drug Administration (FDA) has accepted its efgartigimod subcutaneous injection formulation for the treatment of adult patients with generalized myasthenia gravis (gMG) and granted priority review status.
-
Express Durable prevention of multiple sclerosis deterioration, the new generation of therapy has a positive effect
Time of Update: 2023-01-05
▎WuXi AppTec content team editor Immunic, a biopharmaceutical company focused on developing immunotherapies for the treatment of chronic inflammatory and autoimmune diseases, has announced data from a Phase 2 clinical trial of its primary drug candidate, vidofludimus calcium (IMU-838), for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
Professor Zhou Caicun CameL research: The co-expression of different tumor immune microenvironment
Time of Update: 2023-01-05
Fig. 4 Tumor mutation characteristics of CD8/PD-L1 co-expression positive and negative groups3smallknotThis study mainly explores the predictive value of the expression levels of tumor immune microenvironment biomarkers PD-L1, CD8, CD68, CD4, FOXP3 and their different combinations in patients with locally advanced or metastatic NSCLC treated with PD-1 inhibitors and chemotherapy.
-
Riding on the express train of "carbon neutrality", nuclear power has ushered in new opportunities for development
Time of Update: 2022-11-28
The Central Economic Work Conference will do a good job in carbon peaking and carbon neutrality, and list it as one of the eight key tasks in 2021, and "carbon peaking" and "carbon neutrality" have b
-
Express To benefit more patients with chronic hepatitis B, Gilead Antiviral Therapy has been approved by the FDA to expand its scope
Time of Update: 2022-11-15
▎WuXi AppTec content team editorGilead Sciences today announced that the US FDA has approved a supplemental new drug application (sNDA) for its drug Vemlidy (tenofovir alafenamide) for the treatment of children with chronic hepatitis B.
-
Express prevents multiple sclerosis progression for nearly four years! T cell therapy has shown excellent results
Time of Update: 2022-11-05
▎WuXi AppTec content team editor Atara Biotherapeutics has updated new advances in its Phase 1 clinical trial of ATA188, an allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV), in progressive multiple sclerosis, including new magnetic resonance imaging (MRI) biomarkers and open-label extension (OLE) trial data.
-
Express $1.76 billion! Jazz Pharmaceuticals has acquired the rights to develop and commercialize a HER2-targeted investigational bispecific antibody
Time of Update: 2022-10-25
Retrieved 2022-10-19, from style="display: none;">[1] Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody.
Retrieved 2022-10-19, from style="display: none;">[1] Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody.
-
Express Can Alzheimer's disease be treated without taking medicine? The innovative therapy has been
Time of Update: 2022-10-25
Image source: 123RFThe SinaptiStim-AD system developed by Sinaptica combines neurostimulation devices, brainwave monitoring technology, and the company's proprietary artificial intelligence personalization engine to personalize the patient's brain with electromagnetic waves, a precise, non-invasive treatment that can improve synaptic plasticity and stabilize the connections between brain networks, thereby improving the symptoms of dementia in Alzheimer's patients.
-
Express mRNA Cancer Vaccine in combination with Keytruda! Moderna has teamed up with Merck to target melanoma
Time of Update: 2022-10-20
▎WuXi AppTec content team editorMSD and Moderna today jointly announced that Merck has selected to jointly develop and commercialize the individualized cancer vaccine (PCV) mRNA-4157/V940 with Moderna under an existing collaboration and licensing agreement between the two companies.
-
Express treatment of cholangiocarcinoma, innovative precision therapy has been accelerated by the FDA
Time of Update: 2022-10-13
▎WuXi AppTec content team Editors Today, Japan's Taiho Pharmaceutical and subsidiary Taiho Oncology announced that the US FDA has accelerated the approval of Lytgobi (futibatinib) for the treatment of adult patients with unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma carrying FGFR2 gene fusion or other rearrangement.
-
Express In the treatment of non-small cell lung cancer, GSK has made excellent clinical progress in the development of PD-1 antibodies and TIM-3 inhibitors
Time of Update: 2022-10-13
According to the press release, Jemperli reached the primary endpoint of the trial in the largest head-to-head PD-1 inhibitor trial to date in the metastatic non-small cell lung cancer (NSCLC) patient population.
-
Qian Weiqiang's research group has made new progress in the expression of nitrogen starvation regulated transposons in Arabidopsis
Time of Update: 2022-10-13
JIPB recently published a research paper by Qian Weiqiang's research group of the School of Modern Agriculture of Peking University entitled "Nitrogen starvation induces genome-wide activation of transposon elements in Arabidopsis" 。 Using a forward genetic approach, the study identified glutamate synthase (GLU1) that affects transcriptional level gene silencing, and combined with a series of molecular biology and genetic experiments, explored the effect of nitrogen starvation on activated transposon expression.
-
Express has the potential to reduce brain atrophy! Positive results of the clinical phase 2 of the new drug for Alzheimer's disease were announced
Time of Update: 2022-10-02
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamAlzheon today announced the latest positive results of its investigational drug ALZ-801 (valiltramiprosate) in a Phase 2 biomarker trial.
-
IMS 2022 Express BCMA CAR-T Cell Therapy RRMM Real World Research Data Released! The efficacy
Time of Update: 2022-09-15
【OAB-008】 Efficacy and safety of BCMA CAR-T in the treatment of elderly MM patientsIn the KarMMa trial, PFS was comparable in older patients to younger patients.
【OAB-008】 Efficacy and safety of BCMA CAR-T in the treatment of elderly MM patientsIn the KarMMa trial, PFS was comparable in older patients to younger patients.